EN
Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
Monday December 22, 8:00 am ET
2008 marks only the 30th anniversary of China's reform and market liberation program along with the 20th anniversary of the establishment of the Zhongguancun, a technology hub situated in Beijing that is often referred to as "China's Silicon Valley". The Beijing municipal government recognizes the importance of advancing the development of this technology district that consists of more than 800 companies that contribute approximately 18% of Beijing's GDP. This year, the Beijing municipal government conducted a comprehensive study of experiences and developments within the Zhongguancun district for the last 20 years and named twenty leading technology companies to be the "Top 20 Most Influential Brands". Sinovac and other leading technology companies such as Sina, Lenovo, Aigo, Sohu and New Oriental were the recipients of this prestigious recognition. The award ceremony was held by the Administrative Committee of the Zhongguancun Science Park and was entitled, "Haidian Tells the World - Celebration of the 30th Anniversary of Reform and Liberalization, Celebration of the 20th Anniversary of the Foundation of Zhongguancun Science Park".
Mr. Weidong Yin, Chairman, President and CEO of Sinovac Biotech Ltd., commented, "We are pleased to be named as one of the most influential brands within the Beijing's high technology development zone. This recognition is a testament to Sinovac's commitment to providing comprehensive marketing and sales programs that support our brand in China. In addition, our vaccine research and development capabilities have enabled us to successfully commercialize three vaccines and continue to cultivate our development pipeline."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com .
For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: scarrington@theruthgroup.com jmccargo@theruthgroup.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.